Project Grant R01CA303081
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $745K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $276,545 to The Children's Hospital of Philadelphia Research Institute on June 8, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support the development of genomic risk prediction models for T-cell malignancies. The project, which will be completed by May 31, 2031, addresses a critical clinical need by creating risk stratification tools for relapsed acute lymphoblastic leukemia (ALL) and T-cell...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $457,683 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, with a completion date of March 31, 2028. This award supports the development and preclinical evaluation of a macromolecular prodrug-based drug delivery system designed to enhance chemotherapy efficacy against high-risk neuroblastoma, the most common and deadly...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $197,518 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 8, 2025, through August 31, 2030. This award supports the development of a Rare Tumor Clinical Research Specialist position focused on addressing critical barriers in clinical research for rare cancers, which collectively account for 25% of cancer deaths despite...
- Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $533,245 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 30, 2031. The project investigates protein glutathionylation as a mechanism essential for leukemia-initiating cell (LIC) survival in acute myeloid leukemia (AML). The research aims to develop therapeutic strategies targeting mitochondrial...
- Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded September 11, 2025, with completion by August 31, 2030. The research project targets polyamine metabolism in leukemia stem cells (LSCs) to develop therapeutic interventions for acute myeloid leukemia (AML). The project delivers fundamental research investigating the mechanistic role of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of Pennsylvania a Project Grant totaling $434,969 under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, through April 30, 2031. This research grant supports investigation into the cellular mechanisms underlying FLT3 (Fms-like tyrosine kinase 3)-mutant clone persistence in acute myeloid leukemia (AML) during targeted therapy. The project employs genetically engineered mouse models with...
- Federal Grant Award Summary Children's Hospital Los Angeles received a $573,286 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded May 5, 2026, with completion by April 1, 2031. The award funds research dissecting inter-compartmental tumor-host communication mechanisms driving early dissemination in uveal melanoma (UM), a rare ocular cancer with high propensity for hepatic metastasis. The project delivers fundamental cancer...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $768,713 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025, through July 31, 2030. This award supports fundamental research to advance understanding of epigenetic mechanisms controlling neuroblastoma cell state plasticity and treatment resistance. The project specifically investigates the role of histone...